Indications for ARCAPTA NEOHALER:
Long-term maintenance treatment of bronchoconstriction in patients with COPD, including chronic bronchitis and/or emphysema.
For oral inhalation use only with Neohaler device; do not swallow caps. Remove cap from blister pack immediately before use. Inhale contents of one 75mcg cap daily.
LABA use in asthma patients without use of long-term control medication.
Long-acting beta2-adrenergic agonists increase the risk of asthma-related death.
LABAs increase risk of asthma-related death. Not recommended for treating asthma or acute deteriorations of COPD. Do not exceed recommended dose. Not for primary treatment of acute symptoms. Prescribe a short-acting β2-agonist for acute symptoms; monitor for increased need. Discontinue if paradoxical bronchospasm or cardiovascular effects occur. Cardiovascular disease (esp. coronary insufficiency, arrhythmias, hypertension). Convulsive disorders. Thyrotoxicosis. Hyperresponsiveness to sympathomimetics. Hypokalemia. Hyperglycemia. Diabetes. Ketoacidosis. Severe hepatic impairment. Pregnancy (Cat.C). Labor & delivery. Nursing mothers.
Long-acting beta-2 agonist (LABA).
See Contraindications. Avoid other sympathomimetics (except short-acting bronchodilators). Extreme caution with MAOIs, tricyclics, others that prolong QTc interval. Antagonized by β-blockers. K+-depleting diuretics, theophylline, aminophylline, steroids may potentiate hypokalemia.
Cough, oropharyngeal pain, nasopharyngitis, headache, nausea; hypersensitivity reactions (discontinue immediately and use alternative therapy).
Blister pack—30 + one Neohaler device